Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Boehringer Ingelheim Limited
Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
Telephone: +44 (0)1344 424 600
Fax: +44 (0)1344 741 298
WWW: http://www.boehringer-ingelheim.co.uk
Medical Information Direct Line: +44 (0)1344 741 286
Medical Information e-mail: medinfo@bra.boehringer-ingelheim.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 06/02/2012
PIL Viramune 200mg Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 06/02/2012 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to instructions about missed dose
  • Change to MA holder contact details
Updated on 21/07/2011 and displayed until 06/02/2012
Reasons for adding or updating:
  • Correction of spelling/typing errors
  • Change to date of revision
  • Change to side-effects
  • Change to information about driving or using machinery
  • Change to dosage and administration
Updated on 20/09/2010 and displayed until 21/07/2011
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to MA holder contact details
Updated on 24/07/2009 and displayed until 20/09/2010
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 27/04/2009 and displayed until 24/07/2009
Reasons for adding or updating:
  • Change to drug interactions
  • Change to manufacturer contact details
  • Introduction of new pack/pack size
Updated on 20/08/2008 and displayed until 27/04/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to date of revision
Updated on 03/04/2008 and displayed until 20/08/2008
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 01/04/2008 and displayed until 03/04/2008
Reasons for adding or updating:
  • Change to drug interactions
  • Change to dosage and administration
  • Change to side-effects
  • Change to warnings or special precautions for use
Updated on 08/08/2006 and displayed until 01/04/2008
Reasons for adding or updating:
  • Change to date of revision
Updated on 12/05/2006 and displayed until 08/08/2006
Reasons for adding or updating:
  • Change to date of revision
Updated on 24/06/2005 and displayed until 12/05/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 04/03/2005 and displayed until 24/06/2005
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 21/01/2002 and displayed until 04/03/2005
Reasons for adding or updating:
  • Update to PIL
Updated on 18/01/2001 and displayed until 21/01/2002
Reasons for adding or updating:
  • No reasons supplied
Updated on 31/08/2000 and displayed until 18/01/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 13/06/2000 and displayed until 31/08/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  nevirapine